VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH &#8804; 150 pg/mL: results of the Italian FARO Survey by M. Cozzolino et al.
Nephrol Dial Transplant (2012) 27: 3588–3594
doi: 10.1093/ndt/gfs108
Advance Access publication 20 April 2012
VDRA therapy is associated with improved survival in dialysis
patients with serum intact PTH ≤150 pg/mL: results of the Italian
FARO Survey
Mario Cozzolino1, Diego Brancaccio2, Giuseppe Cannella3, Piergiorgio Messa4, Loreto Gesualdo6,
Martino Marangella6, Cosimo LoDeserto7, Marco Pozzato8, Giuseppe Rombolà9, Anna
Maria Costanzo10, Umberto di Luzio Paparatti10, Sandro Mazzaferro11 and on behalf of the FARO
Study Group
1Renal Division, Dipartimento di Medicina, Chirurgia e Odontoiatria, University of Milan, San Paolo Hospital, Milan, Italy,
2Dialysis Unit, “Simone Martini”, Milan, Italy, 3Department of Nephrology, San Martino Hospital, Genoa, Italy, 4Department of
Nephrology, Policlinico Hospital, Milan, Italy, 5Department of Biomedical Science, University of Bari, Bari, Italy, 6Mauriziano
Umberto I Hospital, Torino, Italy, 7Department of Nephrology, Taranto Hospital, Taranto, Italy, 8Department of Nephrology,
S. Giovanni Bosco Hospital, Torino, Italy, 9Department of Nephrology, S. Andrea Hospital, La Spezia, Italy, 10Abbott Italy,
Campoverde, Latina, Italy and 11Department of Clinical Science, Sapienza University, Rome, Italy
Correspondence and offprint requests to: Mario Cozzolino; E-mail: mario.cozzolino@unimi.it
Abstract
Background. Chronic kidney disease (CKD) patients af-
fected by mineral bone disorders (MBD) have higher
rates of all-cause and cardiovascular-related mortality.
Approximately, one-third of dialysis patients have low
serum parathyroid hormone (PTH) levels (≤150 pg/mL).
However, the reason why these patients have higher mor-
tality compared to patients with normal PTH levels has
not yet been fully elucidated.
Methods. The FARO study was performed on 2453
Italian patients followed prospectively from 28 dialysis
centres over a 2-year period. Data were collected every 6
months and end points included time-to-death cumulative
probability in patients with serum intact PTH (iPTH)
≤150 pg/mL and the effect of vitamin D receptor acti-
vation (VDRA) therapy. Kaplan–Meier curves and pro-
portional hazards regression models stratiﬁed by PTH
levels (i.e. ≤150 and >150 pg/mL) were used to deter-
mine cumulative probability of time-to-death and adjusted
hazard ratios (HRs) for demographic, clinical and CKD-
MBD treatment characteristics.
Results. The cumulative probability of death was
higher (P < 0.01) for patients with serum iPTH levels
≤150 pg/mL [25.1%, 95% conﬁdence interval (CI):
22.1–28.5 at 18 months] versus those with serum iPTH
levels within the normal range (18.0%, 95% CI: 16.1–
20.1). In a model with time-dependent covariates re-
stricted to time periods when patients had iPTH levels
≤150 pg/mL, lower mortality was observed in patients
treated with VDRA [i.e. HR = 0.62, 95% CI: 0.42–0.92
for oral or intravenous (IV) calcitriol; HR = 0.18, 95%
CI: 0.04–0.8 for IV paricalcitol] versus those not re-
ceiving any VDRA (P < 0.01) independently of other
variables. Patients who received IV paricalcitol, com-
pared with either oral or IV calcitriol, showed reduced
mortality, but this was not statistically signiﬁcant (HR
= 0.3, 95% CI: 0.07–1.31, P = 0.11).
Conclusion. Results from this observational study
suggest that VDRA therapy was associated with im-
proved survival in dialysis patients, even with low
serum iPTH levels.
Keywords: calcitriol; CKD-MBD; haemodialysis; paricalcitol; PTH
Introduction
Patients with chronic kidney disease (CKD) who are af-
fected by mineral bone disorders (MBD) have been
shown to have higher rates for both all-cause and cardio-
vascular-related mortality. In fact, CKD is associated with
lower circulating levels of 1α,25-dihydroxyvitamin D3
(1,25-D) [1, 2], inducing serious clinical implications,
such as reduction in intestinal calcium (Ca) absorption,
impairment of skeletal density, increase in parathyroid
hormone (PTH) production and dysregulation of phos-
phorus (P) metabolism [3, 4]. Thus, maintaining sufﬁcient
levels of vitamin D is important for maintaining mainly
bone health. On the contrary, excessive exogenous treat-
ment with active 1,25-D (i.e. calcitriol) may result in ab-
normally elevated mineral levels, which are associated
with increased risk of morbidity (e.g. vascular calciﬁca-
tion) and mortality [5, 6]. In order to maximize the ben-
eﬁcial effects of 1,25-D, while reducing the risks
associated with excessive calcitriol treatment, several syn-
thetic vitamin D receptor activators (VDRAs) have been
developed, which are efﬁcacious in treating CKD-MBD
[3, 7, 8, 9].
For several decades, VDRA therapy has been used as
the mainstay therapy for CKD-MBD in patients receiving
© The Author 2012. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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haemodialysis (HD) [10, 11]. This therapy has been sig-
niﬁcantly associated with a reduction in all-cause [12, 13,
14] and cardiovascular-related mortality rates [13, 15, 16].
Inadequate or late treatment of CKD-MBD is associated
with enhanced bone and cardiovascular disease [17].
Reduced 1,25-D levels and, thus, limited vitamin D receptor
activation (VDRA) in CKD patients result in elevated serum
PTH levels, which may play a role in the high prevalence of
cardiovascular disease observed in this population [18]. Sur-
prisingly, a high proportion of dialysis patients have low
serum PTH levels, but why they have higher mortality com-
pared to patients with serum PTH levels in the normal range
has not yet been fully elucidated [19, 20, 21]. Usually, dialy-
sis patients with low serum PTH levels do not receive any
form of active vitamin D to avoid a further reduction of PTH
and increase the risk of adynamic bone disease [22, 23, 24].
Data from the prospective Accelerated Mortality on
Renal Replacement (ArMORR) study in HD patients cor-
related low circulating levels of 25-dihydroxyvitamin D3
and 1,25-D with increased all-cause and cardiovascular
mortality [25] and indicated that survival was signiﬁcantly
improved in patients receiving VDRA therapy compared
with untreated patients [25, 26]. Even in patients with less
severe stages of CKD (i.e. Stages 3–5) who have yet to
begin HD, calcitriol was associated with a signiﬁcant sur-
vival beneﬁt [27, 28].
The Kidney Disease Outcomes Quality Initiative
(K/DOQI) updated their international guidelines in 2003
with regard to target levels for serum intact PTH (iPTH),
Ca and P in an effort to help lower secondary hyperpar-
athyroidism (SHPT)-related mortality [22]. Studies exam-
ining the long-term safety of VDRAs in CKD patients
with SHPT who achieve these K/DOQI target ranges are
currently lacking. Therefore, using data from FARO, an
Italian survey of dialysis patients with SHPT that assessed
their position within or outside of KDOQI target ranges
[29], the clinical outcome of VDRA therapy on mortality
was examined in the present study.
Materials and methods
Study design
The FARO study was a prospective multicentre survey of treatment prac-
tices undertaken from April 2006–October 2007 in 28 dialysis centres in
Italy [29]. Brieﬂy, patient questionnaires were completed at each centre
in four 1-week sessions, evenly distributed over an 18-month period
(baseline, Month 6, Month 12 and Month 18) and subsequently reviewed
and approved by the physician in charge. This survey was designed, so
patients could enter or exit a given dialysis centre over the course of the
18-month period, resulting in variation in sample sizes for each of the
four surveys (e.g. new patient, death or transfer to another centre).
Further details of the study design have been published elsewhere [29].
All patients provided written informed consent and the study was in
compliance with the Italian Legislative Decree 196/2003.
Mortality risk assessments
For patients with Stage 5 CKD on HD, we used the 2003 guidelines of
the Kidney Disease Outcomes Quality Initiative (KDOQI) of the Na-
tional Kidney Foundation that recommend speciﬁc targets, including
serum iPTH levels from 150 to 300 pg/mL [22]. A recent European ob-
servational study showed the lowest risk of mortality among patients
with iPTH values within the KDOQI target range, further supporting the
use of this iPTH range [30]. In fact, the 2009 Kidney Disease–Improving
Global Outcomes (KDIGO) guidelines were not yet available at the time
this study was designed [31]. iPTH was measured by second-generation
commercially available kits. The commercially available kits used were
not identical across all dialysis centres. Risk of all-cause mortality by
iPTH levels (≤150 versus >150 pg/mL) was assessed using a time-de-
pendent model in all patients at each post-baseline session (i.e. Months
6, 12 and 18). A model of time-dependent covariates restricted to
periods when patients had iPTH ≤150 pg/mL was also used to assess the
effect of VDRA therapy [untreated, oral/intravenous (IV) calcitriol or IV
paricalcitol] on survival (all-cause mortality).
Time to all-cause mortality hazard ratios (HRs) were assessed for
patients with iPTH ≤150 pg/mL and adjusted for various demographic
and clinical values, including dialysis vintage (per 10-year increase), age
(per 10-year increase), sex, comorbidities and history of diabetes. Time-
dependent variables included serum albumin (per 1-unit increase),
serum haemoglobin (per 1-unit increase), serum phosphorus (≤3.5
versus >3.5 to ≤5.5 and >5.5 versus >3.5 to ≤5.5 mg/dL), serum
calcium (≤8.4 versus >8.4 to ≤9.5, >9.5 to ≤10.5 versus >8.4 to ≤9.5
and >10.5 versus >8.4 to ≤9.5 mg/dL). Patients who moved or were
transferred to other dialysis centres or who were lost to follow-up (168 in
total) were censored as alive at the last visit performed.
Statistical analysis
The Kaplan–Meier (KM) method was used to estimate the cumulative
probability of all-cause mortality in all patients and stratiﬁed by iPTH
level (i.e. ≤150 versus >150 pg/mL). KM survival estimates were also
performed for patients who had iPTH ≤150 pg/mL to assess the effect
of VDRA therapy on all-cause mortality in this patient subgroup. Strati-
ﬁed (by iPTH level) Cox proportional hazard regression models were
used to estimate time to all-cause mortality HRs. For each HR, the 95%
conﬁdence interval (CI) was computed. This analysis was adjusted for
all potential confounders and variables that changed during the follow-
up were included as time-dependent covariates. In the few cases, when a
measurement had missing information, the last available value was used.
All Cox proportional hazard regression models were stratiﬁed by each
participating clinical centre. A P-value of <0.05 was considered statisti-
cally signiﬁcant. Statistical analyses were performed using SAS (version
8.2 for WindowsTM, Cary, NC) and STATA (version 8.0; College
Station, TX) software.
Results
Disposition, demographic and clinical characteristics
Disposition, demographic and clinical characteristics for
patients who participated in this survey are previously de-
scribed [29]. Brieﬂy, of 2637 patients initially included in
the study, 2453 were included in the current analysis. A
total of 184 patients were excluded for the following
reasons: 146 (5.54%) were lost to follow-up after partici-
pating in a single survey period, 29 (1.1%) received treat-
ment other than oral or IV calcitriol or IV paricalcitol and
9 (0.34%) were deceased prior to the ﬁrst study session.
Sample sizes for each of the four 1-week sessions varied
due to changes in patient exit and entry over the 18-
month period (baseline, n = 2453; Month 6, n = 2437;
Month 12, n = 2079 and Month 18, n = 1736). All further
analysis was based on the following patient subgroups:
serum iPTH levels of ≤150 and/or >150 pg/mL. Baseline
demographic and clinical characteristics for the two
patient groups are presented in Table 1. Demographic
characteristics were similar between the two groups.
Although the majority of comorbid conditions remained
unchanged between patient subgroups, the number of
patients with left ventricular hypertrophy was signiﬁcantly
higher in patients with elevated iPTH (>150 pg/mL; 57.5
versus 52.9%, P < 0.014). In contrast, a higher proportion
of patients with iPTH ≤150 pg/mL had cerebrovascular
disease (14.8 versus 10.9%, P = 0.011).
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Mineral metabolism-related treatment
Subgroup analysis of the number of HD patients with
either low or high levels of iPTH (≤150 or >150 pg/mL)
receiving VDRA or phosphate-binding therapy for the
four visits is summarized in Table 2. At baseline, the
majority of patients were treated with oral calcitriol (87%
in the ‘low’ iPTH group and 55.8% in the ‘high’ iPTH
group). The percentage of patients (for both iPTH groups)
treated with oral calcitriol also decreased gradually over
the four visits. In contrast, few patients from either iPTH
subgroups were administered calcitriol intravenously (5.5
versus 18.5% at baseline) and no change was observed
over the course of the survey period. The number of
patients administered paricalcitol (IV) increased gradually
over the four visits in both patient subgroups, a greater pro-
portion of patients with iPTH >150 pg/mL receiving this
medication compared to patients with iPTH levels ≤150
pg/mL. Approximately half of patients (in either iPTH
subgroup) received phosphate-binding therapy and the
proportion of these patients did not change over the four
visits.
Survival estimates in HD patients: effect of PTH levels
and VDRA therapy
The cumulative risk of all-cause mortality was signiﬁ-
cantly lower over the course of the survey for patients
with serum iPTH >150 pg/mL compared to patients with
serum iPTH levels of ≤150 pg/mL (P < 0.01, Figure 1).
The time course presented in Figure 1 shows that the
event curves for iPTH >150 pg/mL patients compared
with the iPTH ≤150 pg/mL group had already separated
at 6 months and continued to further diverge for the dur-
ation of the study. Examining the effect of VDRA treat-
ment in the subgroup of patients with serum iPTH levels
of ≤150 pg/mL revealed that VDRA-treated patients (cal-
citriol or paricalcitol) had lower mortality rates compared
to untreated patients (P < 0.01, Figure 2). Furthermore,
patients treated with paricalcitol (IV) were observed to
have improved survival rates (as early as 10 months) com-
pared to calcitriol-treated patients, but this was not statisti-
cally signiﬁcant (P = 0.11, Figure 2).
The effect of demographic and clinical variables on
survival
Table 3 shows time to death in HD patients after stratify-
ing by major clinical variables. In patients with serum
iPTH ≤150 pg/mL, clinical variables that signiﬁcantly
Table 1. Demographic and clinical characteristics of the study
populationa
Clinical characteristics PTH ≤150





Men, n (%) 506 (61.5) 1025 (62.9)
Women, n (%) 317 (38.5) 605 (37.1) 0.48
Age, years (range) 68 (58–77) 68 (56–75) 0.067
Dialysis vintage,
months (range)
30 (10–72) 39 (12–81) 0.053
Comorbid conditions
Hypertension, n (%) 540 (65.6) 1104 (67.7) 0.31
Dyslipidaemia, n (%) 144 (17.5) 325 (19.9) 0.15
Diabetes, n (%) 132 (16) 240 (14.7) 0.37
Left ventricular
hypertrophy, n (%)
435 (52.9) 937 (57.5) 0.014
CAD, n (%) 182 (22.1) 378 (23.2) 0.37
PAD, n (%) 191 (23.2) 323 (19.8) 0.089
Cerebrovascular
disease, n (%)
122 (14.8) 178 (10.9) 0.011
Laboratory
iPTH (pg/mL) 78 (40–113) 345 (235–502) <0.001
Serum phosphorus
(mg/dL)
4.7 (3.9–5.6) 5.1 (4.4–5.9) <0.001
Serum calcium
(mg/dL)
9.1 (8.6–9.5) 9 (8.5–9.6) 0.79
Haemoglobin (g/dL) 11.3 (10.5–12) 11.4 (10.5–12.1) 0.22
Serum albumin
(g/dL)
3.7 (3.4–4) 3.8 (3.4–4.1) 0.005
aCAD, coronary artery disease; PAD, peripheral artery disease.
Table 2. Mineral metabolism related treatments by visita
























VDRAs, n (%) 253 (30.7) 977 (59.9) 239 (29.9) 1025 (62.6) 231 (34.8) 933 (65.9) 231 (40) 799 (69)
Calcitriol, PO (%)
87 55.8 75.7 48.4 72.3 39.5 63.2 36.9
Calcitriol, IV (%)
5.5 18.5 3.8 17.2 6.5 15.8 5.6 14.5
Paricalcitol,
IV (%)
4 24.4 12.6 28 10.4 38.7 20.8 41.9




55.2 43.9 50.2 42.6 48.6 43.5 48.8 41.6
Calcium-
free (%)
47.3 58.9 45.1 57.9 41.4 60.8 41.9 60.4
aN refers to the frequency of patients; the per cent of VDRAs and phosphate binders also includes combination use. IV, intravenous; PO, oral.
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increased time to death were age, presence of cerebrovas-
cular disease, increased albumin or haemoglobin. VDRA
treatment was associated with lower all-cause mortality
HRs. Oral or IV calcitriol (HR = 0.62, 95% CI: 0.42–
0.92, P = 0.02) or IV paricalcitol (HR = 0.18, 95% CI:
0.04–0.8, P = 0.02) was associated with statistically sig-
niﬁcant reductions in time to death compared to patients
who did not receive VDRA therapy (Table 3).
Discussion
Results from this analysis of the FARO survey suggest
that VDRA treatment is associated with reduced overall
mortality as well as factor-adjusted mortality risks among
Italian dialysis patients with SHPT, even when serum
iPTH levels are ≤150 pg/mL. In addition, patients who
did not receive treatment had a poorer prognosis. Survival
data from the present study also suggest that paricalcitol is
associated with an improvement over calcitriol for lower-
ing the risk of all-cause mortality [32]. Our ﬁndings are
conﬁrmed by Teng et al. who performed a large (N = 67
399) retrospective analysis that showed a signiﬁcantly
lower mortality rate among HD patients receiving IV par-
icalcitol compared with those receiving IV calcitriol [33].
Furthermore, patients receiving paricalcitol who switched
to calcitriol had signiﬁcantly higher mortality rates than
those receiving calcitriol who switched to paricalcitol; the
overall survival advantage attributed to paricalcitol over
calcitriol was 16% [33]. Another retrospective database
analysis by Tentori et al. (N = 7731) observed that mortality
rates were also signiﬁcantly lower in HD patients treated
with paricalcitol (or doxercalciferol) compared with those
treated with calcitriol (P < 0.05) [14]. Although these ﬁnd-
ings favour the use of vitamin D, differences between the
different compounds were not statistically signiﬁcant fol-
lowing adjustment for patient characteristics.
More recently, Tentori et al. [34] compared different
methods for evaluating the clinical impact of vitamin D
and observed that previously published Dialysis Out-
comes and Practice Patterns Study data [35] may have
been distorted by potential confounders that could not be
measured, even if in this study there were HD patients
treated with oral vitamin D that included the native form.
Therefore, the beneﬁt afforded by VDRA treatment on
survival in patients on HD remains to be veriﬁed in a pro-
spective randomized clinical trial even if we consider that
in this analysis, the overall unadjusted mortality rate was
16 deaths per 100 patient-years. Furthermore, among
patients prescribed and not prescribed vitamin D, death
rates were 14 and 17.9 per 100 patient-years, respectively,
and this difference persisted even when data were adjusted
for demographic confounders. Although the present study
was not designed to assess how speciﬁc VDRA dosing
regimens affected patient survival, it is important to con-
sider dosage ranges when discussing mortality data to de-
termine clinical relevance. Patients who participated in
the FARO study received weekly mean doses of oral cal-
citriol, IV calcitriol or IV paricalcitol which ranged from
1.9 to 2.2, 3.4 to 3.7 and 11.2 to 15.9 μg, respectively,
depending on the study visit [32]. Other evidence
suggests that VDRAs at similar or higher doses are
capable of providing signiﬁcant clinical beneﬁt in these
patients [12, 15, 34]. A time-dependent, 2-year prospec-
tive analysis of patients on maintenance HD therapy (N =
58 058) by Kalantar-Zadeh et al. [12] demonstrated that
even lower doses of paricalcitol (1–4.99 μg/week) were
associated with reductions in all-cause mortality HRs.
Further analysis on a subset of patients (N = 34 307) from
the same database revealed that HD patients who received
an average weekly dose of IV paricalcitol (14.3 μg/week)
comparable to that of patients in our study, also experi-
enced signiﬁcant reductions in the relative risk of death
compared with untreated patients [34]. A recent historical
cohort study of chronic HD patients in Latin American
Fig. 2. KM plot of survival estimates by VDRA treatment type.
Survival estimates (all-cause mortality) for FARO patients with levels of
serum iPTH ≤150 pg/mL treated with paricalcitol (semi-solid line; HR:
0.13, 95% CI: 0.03–0.54, P < 0.01) or calcitriol (solid line; HR: 0.62,
95% CI: 0.43–0.89, P < 0.01) versus untreated patients (dotted line).
Fig. 1. KM plot of survival estimates by iPTH levels. Survival estimates
(all-cause mortality) for FARO patients with levels of serum iPTH >150
pg/mL (dotted line) versus patients with levels of serum iPTH ≤150 pg/
mL (solid line; P < 0.01).
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dialysis sites demonstrated signiﬁcant overall survival beneﬁt
of oral active VDRA (97% calcitriol) using a mean daily
dose as high as 0.51–1 μg and as low as <0.25 μg compared
to no VDRA therapy [15]. This study showed that mean
daily doses of oral active vitamin D <1 μg showed a signiﬁ-
cant beneﬁt in survival rate. Interestingly, the reduction in
mortality risk was even seen at the lowest PTH tertile, where
a higher tendency in mortality risk has previously been de-
scribed [36] and accompanied with high serum calcium and
phosphorus levels [33]. Although these studies do suggest
an overall dose-related survival beneﬁt afforded by VDRA
therapy, a recent large observational study by Shinaberger
et al. [37] failed to show any meaningful association
between the absolute dosage of paricalcitol and survival
among maintenance HD patients. However, increasing levels
of the ratio of paricalcitol dosage to serum concentration of
PTH were associated with better survival. These ﬁndings
need to be conﬁrmed in clinical trials.
As previously reported, approximately two-thirds of all
patients in the FARO study failed to achieve target iPTH
levels and nearly 90% failed to achieve combined target
iPTH, P and Ca levels as described by the K/DOQI guide-
lines [22, 29], indicating that the achievement of K/DOQI
target ranges may be difﬁcult for many CKD patients
with SHPT. Therefore, the reassessment of K/DOQI target
ranges may be warranted to determine if they are too
strict, also prompted by considering new target values re-
ported in KDIGO guidelines. Regardless, the impact on
survival is clear. VDRA therapy was shown to be signiﬁ-
cantly associated with a reduced risk of all-cause mor-
tality among all the FARO survey patients, even in
patients with serum iPTH levels of ≤150 pg/mL.
There are several limitations to the FARO survey that
need be addressed. The sample size was smaller than
desired, heterogeneous and treatment duration varied
between patients. It is likely that this heterogeneity
(therapy and population characteristics) was attributed to
differences in resources available (treatment resources,
medical experience/knowledge and ﬁnancial resources)
between different clinical centres. Thus, further studies in
larger and more homogeneous patient populations are
warranted. However, despite the relatively short obser-
vation period (i.e. 18 months), we were still able to
observe signiﬁcant differences in patient mortality risk
between treatment groups. A common weakness with ob-
servational studies is the potential for confounding by
indication, which may have also been relevant in the
present study [38]. Trends suggested that more robust
differences may have been evident if a larger sample size
and a longer observation period had been evaluated. The
lack of a standardized therapy resulted in a relatively het-
erogeneous non-randomized patient population including
both prevalent and incident dialysis patients and thus pre-
vented the possibility of comparing different dosing
regimes within treatment groups. iPTH was measured
using commercially available kits. Although each centre
did not change the usual method of assay during the
study period [29], thus maintaining optimized conditions,
identical kits were not used across the various centres.
This poses a potential limitation since it is recognized that
heterogeneity exists between iPTH measurement for
different commercially available kits [39, 40].
In conclusion, these data suggest that VDRAs may be
crucial in decreasing all-cause and mortality in HD
patients. Moreover, paricalcitol may provide an improve-
ment over calcitriol-treated patients even when levels of
serum iPTH are ≤150 pg/mL. The beneﬁt of VDRA treat-
ment on survival in HD patients remains to be conﬁrmed
in large prospective randomized clinical trials.
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Abstract
Background. Predictors of haemoglobin (Hb) levels and
resistance to erythropoiesis-stimulating agents (ESAs) in
dialysis patients have not yet been clearly deﬁned. Some
mainly uncontrolled studies suggest that online haemodia-
ﬁltration (HDF) may have a beneﬁcial effect on Hb,
whereas no data are available concerning online haemoﬁl-
tration (HF). The objectives of this study were to evaluate
the effects of convective treatments (CTs) on Hb levels
and ESA resistance in comparison with low-ﬂux haemo-
dialysis (HD) and to evaluate the predictors of these out-
comes.
Methods. Primary multivariate analysis was made of a
pre-speciﬁed secondary outcome of a multicentre, open-
label, randomized controlled study in which 146 chronic
HD patients from 27 Italian centres were randomly
assigned to HD (70 patients) or CTs: online pre-dilution
HF (36 patients) or online pre-dilution HDF (40 patients).
Results. CTs did not affect Hb levels (P = 0.596) or ESA
resistance (P = 0.984). Hb correlated with polycystic
kidney disease (P = 0.001), C-reactive protein (P = 0.025),
ferritin (P = 0.018), ESA dose (P < 0.001) and total
cholesterol (P = 0.021). The participating centres were
the main source of Hb variability (partial eta2 0.313,
P < 0.001). ESA resistance directly correlated with serum
ferritin (P = 0.030) and beta2 microglobulin (P = 0.065);
participating centres were again a major source of var-
iance (partial eta2 0.367, P < 0.001). Transferrin saturation
did not predict either outcome variables (P = 0.277 and P
= 0.170).
Conclusions. In comparison with low-ﬂux HD, CTs did
not signiﬁcantly improve Hb levels or ESA resistance.
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